Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 3/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053006 | 0.87 | ADORA2A (0.48) | ADORA1SMN1; SMN2 | |
| Calcium SCHEMBL5323177 | 0.86 | ADORA2A (0.47) | ADORA1SMN1; SMN2 | |
| SCHEMBL7084738 | 0.83 | TAS1R3 (0.45) | TAS1R3TAS1R1 | |
| SCHEMBL31032835 | 0.82 | P2RY1 (0.49) | P2RY1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL24059941 | 0.80 | P2RY1 (0.59) | P2RY1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL1300019 | 0.79 | TAS1R3 (0.56) | P2RY1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL18486644 | 0.77 | P2RX1 (0.54) | P2RY1TRPM2SRCP2RY2SMN1; SMN2 | |
| SCHEMBL18486587 | 0.77 | P2RX1 (0.55) | P2RY1TRPM2SRCP2RY2SMN1; SMN2 | |
| SCHEMBL16108838 | 0.76 | P2RY1 (0.59) | P2RY1DNPH1PRKAB2TRPM2LDHA | |
| Pyrophosphoric Acid SCHEMBL18486634 | 0.76 | ADORA1 (0.47) | P2RY1DNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030228564-A1 | Nitric oxide in a pathogen inactivation process | EDRICH RICHARD ALAN (US) | 2003-12-11 | — | — | US | claimed |
| WO-2003066109-A1 | NITRIC OXIDE IN A PATHOGEN INACTIVATION PROCESS | GAMBRO, INC. (US) | 2003-08-14 | — | — | WO | claimed |
| CN-117866021-A | Purification method of acylation liquid and preparation method of dibutyryl adenosine cyclophosphate | 上海上药第一生化药业有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-115916962-A | Repeat dosing of low immunogenic cells | 萨那生物技术股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115768446-A | Low-immunogenicity neural cells for treating neurological disorders and conditions | 萨那生物技术股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-1020517-A4 | GENE ORIGINATING IN HUMAN CHONDROCYTE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20030228564-A1 | Nitric oxide in a pathogen inactivation process | EDRICH RICHARD ALAN (US) | 2003-12-11 | — | — | US | disclosed |
| WO-2003066109-A1 | NITRIC OXIDE IN A PATHOGEN INACTIVATION PROCESS | GAMBRO, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-1999002677-A1 | GENE ORIGINATING IN HUMAN CHONDROCYTE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030228564-A1 | Nitric oxide in a pathogen inactivation process | PFKP, G6PD, NOS2 | P2RY1 391/4885DNPH1 909/4885PRKAB2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.